Featured Jobs
|
Retirement Solutions Specialists
|
|
Pollard & Associates
|
|
Great Lakes Pension Associates, Inc.
|
|
New York City District Council of Carpenters Benefit Funds
|
|
Fringe Benefit Group
|
|
Greenline Wealth Management
|
|
Retirement Planners and Administrators (RPA)
|
|
Defined Contributions Compliance Consultant Loren D. Stark Company (LDSCO)
|
|
TPA Retirement Plan Consultant EPIC RPS (TPA/DPS)
|
|
Defined Contribution Account Manager Nova 401(k) Associates
|
|
Senior Specialist 401k Recordkeeping T Bank N.A.
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
Pharma CEO Jacks Drug Price 400%, Citing 'Moral Requirement to Make Money'
Ars Technica 
Sept. 13, 2018
"Nirmal Mulye, CEO of the small Missouri-based drug company Nostrum Laboratories, raised the price of bottle of nitrofurantoin from $474.75 to $2,392 last month. The drug is a decades-old antibiotic used to treat urinary-tract infections caused by Escherichia coli and certain other Gram-negative bacteria. The World Health Organization lists nitrofurantoin as an essential medicine."
|
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |
© 2024 BenefitsLink.com, Inc.